Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Top-line, 6-month data from the open-label, international Phase II 008 trial in 150 patients showed that ipilimumab
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury